Valproic acid fails to induce polycystic ovary syndrome in female rats

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 4, 2003, Pages 587-594

  Lagace, Diane C ^a   Nachtigal, Mark W ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Bipolar disorder; Epilepsy; Polycystic ovary syndrome (PCOS); Rat; Valproic acid

Indexed keywords

AROMATASE; BUFFER; ESTRADIOL; LEPTIN; PHOSPHATE; SODIUM CHLORIDE; TESTOSTERONE; VALPROATE SEMISODIUM; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CORPUS LUTEUM; DIESTRUS; ENZYME ACTIVITY; ESTRADIOL BLOOD LEVEL; FEMALE; METESTRUS; NONHUMAN; OVARY FOLLICLE; OVARY POLYCYSTIC DISEASE; PROESTRUS; PROSPECTIVE STUDY; RAT; STATISTICAL SIGNIFICANCE; TESTOSTERONE BLOOD LEVEL; WEIGHT GAIN;

EID: 0038689061     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(03)00045-9     Document Type: Article

References (42)

1. Top 200 drugs ranked by dispensed total prescriptions. Pharm. Times April. 1998;42-49.
2. Bauer J., Jarre A., Klingmuller D., Elger C.E. Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res. 41:2000;163-167.
3. Betts T., Dutton N., Yarrow H. Epilepsy and the ovary (cutting out the hysteria). Seizure. 10:2001;220-228.
4. Brawer J.R., Munoz M., Farookhi R. Development of the polycystic ovarian condition (PCO) in the estradiol valerate-treated rat. Biol. Reprod. 35:1986;647-655.
5. Bruguerolle B., Jadot G., Valli M., Bouyard P. Absence of effects of sodium valproate on the estrous cycle of the rat. C.R. Seances. Soc. Biol. Fil. 176:1982;359-363.
6. Campfield L. Central mechanisms responsible for the actions of OB protein on food intake, metabolism and body energy storage. Ur E. Frontiers of Hormone Research. vol. 26:2000;12-21 Karger, Basel.
7. Chang R.J., Katz S.E. Diagnosis of polycystic ovary syndrome. Endocrinol. Metab. Clin. N. Am. 28:1999;397-408.
8. Cooke G.M., Brawer J.R., Farookhi R. Steroidogenic enzyme activities in rat polycystic ovaries. Can. J. Physiol. Pharm. 71:1993;247-253.
9. Davis L.L., Ryan W., Adinoff B., Petty F. Comprehensive review of the psychiatric uses of valproate. J. Clin. Psychopharmacol. 20:2000;1S-17S.
10. Dewailly D. Definition and significance of polycystic ovaries. Bailliere's Clin. Obstet. Gynaecol. 11:1997;349-368.
11. Dinesen H., Gram L., Andersen T., Dam M. Weight gain during treatment with valproate. Acta Neurol. Scand. 70:1984;65-69.
12. Edwards H.E., MacLusky N.J., Burnham W.M. The effect of seizures and kindling on reproductive hormones in the rat. Neurosci. Biobehav. Rev. 24:2000;753-762.
13. Genton P., Bauer J., Duncan S., Taylor A.E., Balen A.H., Eberle A., Pedersen B., Salas-Puig X., Sauer M.V. On the association between valproate and polycystic ovary syndrome. Epilepsia. 42:2001;295-304.
14. Gregoraszczuk E., Wojtowicz A.K., Tauboll E., Ropstad E. Valproate-induced alterations in testosterone, estradiol and progesterone secretion from porcine follicular cells isolated from small- and medium-sized ovarian follicles. Seizure. 9:2000;480-485.
15. Herzog A.G., Schachter S.C. Valproate and the polycystic ovarian syndrome: final thoughts. Epilepsia. 42:2001;311-315.
16. Isojarvi J.I., Tapanainen J.S. Valproate, hyperandrogenism, and polycystic ovaries: a report of 3 cases. Arch. Neurol. 57:2000;1064-1068.
17. Isojarvi J.I., Laatikainen T.J., Pakarinen A.J., Juntunen K.T., Myllyla V.V. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N. Engl. J. Med. 329:1993;1383-1388.
18. Isojarvi J.I., Laatikainen T.J., Knip M., Pakarinen A.J., Juntunen K.T., Myllyla V.V. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann. Neurol. 39:1996;579-584.
19. Isojarvi J.I., Rattya J., Myllyla V.V., Knip M., Koivunen R., Pakarinen A.J., Tekay A., Tapanainen J.S. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann. Neurol. 43:1998;446-451.
20. Isojarvi J.I., Tauboll E., Pakarinen A.J., van Parys J., Rattya J., Harbo H.F., Dale P.O., Fauser B.C., Gjerstad L., Koivunen R., Knip M., Tapanainen J.S. Altered ovarian function and cardiovascular risk factors in valproate-treated women. Am. J. Med. 111:2001;290-296.
21. Isojarvi J.I., Tauboll E., Tapanainen J.S., Pakarinen A.J., Laatikainen T.J., Knip M., Myllyla V.V. On the association between valproate and polycystic ovary syndrome: a response and an alternative view. Epilepsia. 42:2001;305-310.
22. Lara H.E., Dissen G.A., Leyton V., Paredes A., Fuenzalida H., Fiedler J.L., Ojeda S.R. An increased intraovarian synthesis of nerve growth factor and its low affinity receptor is a principal component of steroid-induced polycystic ovary in the rat. Endocrinology. 141:2000;1059-1072.
23. Lennkh C., Simhandl C. Current aspects of valproate in bipolar disorder. Int. Clin. Psychopharmacol. 15:2000;1-11.
24. Lephart E.D., Simpson E.R. Assay of aromatase activity. Methods Enzymol. 206:1991;477-483.
25. Lobo R.A., Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann. Intern. Med. 132:2000;989-993.
26. Loscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog. Neurobiol. 58:1999;31-59.
27. Montes G.S., Luque E.H. Effects of ovarian steroids on vaginal smears in the rat. Acta Anat. 133:1988;192-199.
28. Murialdo G., Galimberti C.A., Magri F., Sampaolo P., Copello F., Gianelli M.V., Gazzerro E., Rollero A., Deagatone C., Manni R., Ferrari E., Polleri A., Tartara A. Menstrual cycle and ovary alterations in women with epilepsy on antiepileptic therapy. J. Endocrinol. Invest. 20:1997;519-526.
29. Murialdo G., Galimberti C.A., Gianelli M.V., Rollero A., Polleri A., Copello F., Magri F., Ferrari E., Sampaolo P., Manni R., Tartara A. Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy. Clin. Neuropharmacol. 21:1998;52-58.
30. O'Donovan C., Kusumakar V., Graves G., Bird D. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J. Clin. Psychiatry. 64:2002;322-330.
31. Purba H.S., Bhatnagar A.S. A comparison of methods measuring aromatase activity in human placenta and rat ovary. J. Enzyme Inhib. 4:1990;169-178.
32. Pylvanen V., Knip M., Pakarinen A., Kotila M., Turkka J., Isojarvi J.I. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia. 43:2002;514-517.
33. Rasgon N.L., Altshuler L.L., Gudeman D., Burt V.K., Tanavoli S., Hendrick V., Korenman S. Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report. J. Clin. Psychiatry. 61:2000;173-178.
34. Rattya J., Pakarinen A.J., Knip M., Repo-Outakoski M., Myllyla V.V., Isojarvi J.I. Early hormonal changes during valproate or carbamazepine treatment: a 3-month study. Neurology. 57:2001;440-444.
35. Roste L.S., Tauboll E., Berner A., Isojarvi J.I., Gjerstad L. Valproate, but not lamotrigine, induces ovarian morphological changes in Wistar rats. Exp. Toxicol. Pathol. 52:2001;545-552.
36. Solomon C.G. The epidemiology of polycystic ovary syndrome. Prevalence and associated disease risks. Endocrinol. Metab. Clin. N. Am. 28:1999;247-263.
37. Steckelbroeck S., Heidrich D.D., Stoffel-Wagner B., Hans V.H., Schramm J., Bidlingmaier F., Klingmuller D. Characterization of aromatase cytochrome P450 activity in the human temporal lobe. J. Clin. Endocrinol. Metab. 84:1999;2795-2801.
38. Tauboll E., Isojarvi J.I., Harbo H.F., Pakarinen A.J., Gjerstad L. Long-term valproate treatment induces changes in ovarian morphology and serum sex steroid hormone levels in female Wistar rats. Seizure. 8:1999;490-493.
39. Verrotti A., Basciani F., Morresi S., de Martino M., Morgese G., Chiarelli F. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology. 53:1999;230-232.
40. Watanabe G., Taya K., Sasamoto S. Dynamics of ovarian inhibin secretion during the oestrous cycle of the rat. J. Endocrinol. 126:1990;151-157.
41. Watanobe H., Suda T. A detailed study on the role of sex steroid milieu in determining plasma leptin concentrations in adult male and female rats. Biochem. Biophys. Res. Commun. 259:1999;56-59.
42. Wolden-Hanson T., Gidal B.E., Atkinson R.L. Evaluation of a rat model of valproate-induced obesity. Pharmacotherapy. 18:1998;1075-1081.